Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications.

Obesity (Silver Spring, Md.)·2026
Same author

A Microsimulation-Based Approach for Mitigating Societal Bias in Chronic Kidney Disease Data.

Medical decision making : an international journal of the Society for Medical Decision Making·2026
Same author

Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer.

Cancer epidemiology·2026
Same author

Assessment of Oral Anticancer Medicines in Pediatric Patients before the Research to Accelerate Cures and Equity (RACE) Act, 2007-2021.

The Journal of pediatrics·2025
Same author

Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes.

JAMA network open·2025
Same author

GLP-1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi-site cohort of patients with type 2 diabetes.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

30-Year Trends in Microvascular Complications and Treatment in Adolescents With Type 1 Diabetes.

Diabetes care·2026
Same journal

Reactive Hypoglycemia as a Transient Metabolic Phenotype of Stage 1 and 2 Type 1 Diabetes.

Diabetes care·2026
Same journal

Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic Cell Transplantation: A Case Report.

Diabetes care·2026
Same journal

Predicting the Path to Attrition: Multidomain Risk Assessment in Diabetic Foot Ulcer Offloading Randomized Controlled Trials.

Diabetes care·2026
Same journal

Habituation to Elevated Glucose Levels in Type 1 Diabetes: Function and Well-Being in Guideline-Based Versus Typical Glycemic Range.

Diabetes care·2026
Same journal

The Correlation Between Fear and Perceived Frequency of Hypoglycemia and Continuous Glucose Monitoring Metrics in Adults With Type 1 Diabetes Using Diabetes Technology: A One-Year Analysis.

Diabetes care·2026
See all related articles

Related Experiment Videos

Medication adherence and racial differences in A1C control.

Alyce S Adams1, Connie Mah Trinacty, Fang Zhang

  • 1Ambulatory Care and Prevention, Harvard Medical School, Boston, Massachusetts, USA. aadams@hms.harvard.edu

Diabetes Care
|February 1, 2008
PubMed
Summary
This summary is machine-generated.

Racial disparities in type 2 diabetes glycemic control persist despite similar medication adherence. Further research into genetic and environmental factors is crucial for addressing these health inequities.

Related Experiment Videos

Area of Science:

  • Diabetes Mellitus Research
  • Health Disparities
  • Clinical Pharmacy

Background:

  • Type 2 diabetes management requires effective self-care practices, including medication adherence.
  • Racial disparities in glycemic control (measured by A1C) are a significant public health concern.
  • Understanding the determinants of these disparities is essential for developing targeted interventions.

Purpose of the Study:

  • To investigate medication adherence and self-management as potential factors contributing to higher glycemic risk in Black versus White patients with type 2 diabetes.
  • To analyze the impact of medication adherence on racial differences in A1C levels.

Main Methods:

  • Retrospective, longitudinal, repeated-measures design.
  • Analysis of 1,806 adult patients (467 Black, 1,339 White) with newly initiated oral hypoglycemic therapy.
  • Follow-up of at least 12 months post-therapy initiation, with race identified via electronic records and self-report.

Main Results:

  • Black patients presented with higher baseline A1C levels compared to White patients (9.8% vs. 8.9%).
  • Lower average medication adherence was observed in Black patients during the first year of therapy (72% vs. 78%).
  • While medication refills correlated with lower A1C, adjusting for adherence did not resolve the Black-White A1C gap.

Conclusions:

  • Persistent racial disparities in A1C levels were identified, unexplained by medication adherence differences.
  • Solely targeting medication adherence is unlikely to eliminate glycemic control disparities in this population.
  • Further investigation into genetic and environmental factors influencing A1C at diagnosis is recommended for targeted interventions.